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Opposite renal effects of a PGEI analog and prostacyclin in humans.
Renal effects of prostaglandins have been widely investigated in anes-
thetized animals, but in contrast only few studies have been devoted to
healthy and diseased humans. Recently, both prostacyclin and a stable
analog of PGE1, misoprostol, have been available for therapeutic
purposes in clinical conditions associated with peripheral or renal
vasoconstriction; however, the renal effects have not been defined. We
have therefore studied the acute renal effects of P012 5 ng kg/mm
intravenously and of misoprostol, a stable POEI analogue, 400pg orally
in two groups of respectively 8 and 12 healthy supine subjects on
normal sodium diet using sodium, lithium, inulin, PAH and neutral
dextran clearances. PGI2 induced a slight natriuretic effect, a systemic
and renal vasodilation with a decrease in mean arterial pressure from
85.3 1.1 to 80.2 1.6 mm Hg (P < 0.01) and in renal vascular
resistance from 94 6 to 75 5 mm Hg . minim! (P < 0.001). GFR did
not change whereas fractional clearance of dextran decreased over the
34 to 48 A radius range. Applying these changes on a hydrodynamic
model of filtration of macromolecules through water-filled pores, we
calculated that PG!2 decreased the glomerular transcapillary pressure
gradient from 35 1 to 32 1 mm Hg (P < 0.001), decreased
nonsignificantly the ultrafiltration coefficient Kf and did not affect the
membrane parameters rO and toO. Misoprostol had no natriuretic effect,
induced slight renal vasoconstriction and moderate decrease in GFR
from 124 9 to 114 10 mllmin 1.73 m2 (P < 0.001). Fractional
dextran clearances were depressed over the 36 to 42 A radius range
corresponding to a rise in sP from 34 Ito 39 2mm Hg (P < 0.01),
a decrease in Kf and no change in rO and toO. Most of these changes are
likely related to a stimulatory effect of angiotensin II production since
plasma renin activity increased consistently after administration of
misoprostol. Thus, prostacycin and misoprostol exerted contrasting
effects on renal function in healthy humans; these effects are likely
related to depressed baseline renal vascular tone, and to the ability or
not to stimulate renin release in this condition.
Inhibition of endogenous prostaglandins synthesis by cy-
clooxygenase inhibitors exerts little effect on renal function in
healthy subjects, suggesting that PGs do not modulate renal
hemodynamics under physiological conditions [1]. In contrast,
under experimental and clinical circumstances when vasocon-
strictor systems are activated, endogenous vasodilatory pros-
taglandins play a modulator role in preserving renal blood flow,
glomerular filtration, water and sodium excretion [21.
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Recently, prostaglandins or their synthetic analogs have been
advocated for therapeutic purposes in a wide spectrum of
diseases including peripheral occlusive arteriopathies with PGI2
[3] and prevention of peptic ulcer [4] and kidney graft rejection
[5] with the stable PGE1-analog misoprostol. Whereas numer-
ous studies have investigated in anesthetized animals the renal
actions of prostaglandins (PGEs) and P012, which are usually
held as renal vasodilators [6—12], only few data are available in
conscious animals and in healthy or diseased humans.
The aim of the present study was to assess in normal
sodium-repleted humans the acute effects of the PGE1-analog,
misoprostol, and of prostacyclin on renal hemodynamics, and
tubular function. The determinants of glomerular filtration were
further evaluated using the measurement of fractional neutral
dextran clearance and a hydrodynamic model of ifitration as
previously described by Deen et al [13].
Methods
Study population
Twenty healthy normotensive volunteers (12 males, 8 fe-
males) aged 22 to 36 years participated in the study after they
had given their informed consent and after the agreement of the
local Ethics Committee had been obtained. Renal and cardio-
vascular diseases had been excluded by appropriate clinical and
laboratory investigations. All subjects were placed on con-
trolled sodium diet (100 to 120 mmolI24 hr) for at least one week
before the study and compliance was verified by 24-hour urine
sodium excretion on the day preceding the study. None took
any drug during the study, except 500 mg lithium carbonate
given orally at 22:00 p.m. the night before the clearance studies.
Study protocol
Misoprostol study. Eight healthy normotensive volunteers (5
males, 3 females) participated in the study. On arrival at the
laboratory on the day of investigation, each subject drank 600
ml tap water after bladder emptying. Water loading was sus-
tained by drinking 300 ml tap water every 30 minutes during the
study. Measurements were performed in the supine position
and patients stood up only to void. After a priming infusion of
inulin (polyfructosan, mutest®, Laevosan, Linz, Austria), para-
aminohippuric acid (PAH, Nephrotest®, Biologische Arbeitsge-
meinschaft GmbH, Lich, Germany) and dextran 40 (Rheomac-
rodex®, Pharmacia France, 130 mg/kg), clearances were
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performed as previously described [141 using a constant rate
infusion of inulin and PAH and seven consecutive 30-minute
clearance periods. Urine was collected every 30 minutes by
spontaneous voiding and blood specimens were drawn from an
indwelling canula to bracket each collection period. The first
three 30-minute periods constituted the control periods. At the
end of the third control period a single dose of misoprostol®
(Searle Inc.) 400 g was given orally, and its effects were
studied for a further 120 minutes, that is, four 30-minute
periods. The first period following the drug administration was
excluded from analysis to take into account the gastric resorp-
tion of the drug so that only the last three 30-minute periods
were used as experimental periods. Mean arterial pressure
(MAP) was measured using an automatic noninvasive oscillo-
metric technique (Dinamap®, Critikon, Tampa, Florida, cuff
size: 23 x 13 cm) every 10 minutes during clearance evaluation.
Samples for plasma renin activity (PRA) and plasma aldoste-
rone concentration (PAC) were drawn before and 60 minutes
after misoprostol administration and were immediately centri-
fuged and kept frozen at —80°C until assayed.
Prostacyclin study. Twelve healthy normotensive volunteers
(7 males, 5 females) participated in this study that was led
according to a similar protocol including three 30-minute con-
trol periods and three additional 30-minute experimental peri-
ods during which the subjects were intravenously infused with
prostacyclin (Wellcome Lab. Inc.) at a constant rate of 5
ng kg/mm for 90 minutes.
Calculations
Clearances of various substances were calculated according
to the standard clearance formula: C = U X V/P where V is
urine flow, U and P urine and plasma concentrations of the
substance, respectively. All clearances were adjusted for a
body area of 1.73 m2. Inulin and PAH clearances were taken as
glomerular filtration rate (GFR) and effective renal plasma flow
(ERPF), respectively. Renal plasma flow was calculated from
PAH clearance and an extraction coefficient estimated to 0.91
[15]. Mean arterial pressure was calculated as the average of all
recordings during the clearance procedure either before and
after drug administration. Renal vascular resistance (RVR) was
calculated as MAP x (1 — hematocrit)/RPF. Fractional excre-
tion of sodium (FENa) was calculated as CNa/GFR.
Segmental tubular sodium handling was estimated from the
lithium clearance (CLI), on the basis of studies showing that
lithium is reabsorbed in parallel with sodium almost exclusively
in the proximal tubule and in the thick ascending limb of
Henle's loop. Fractional lithium reabsorption was held as an
index of both proximal tubule and loop of Henle reabsorption
[16]. Fractional lithium reabsorption (FRLI) was calculated as 1
— (CLIIGFR) and fractional distal reabsorption of sodium
(FDRNa) as 1 — (CNa/CLi).
Fractional dextran clearances (FCD) were computed using the
equation:
FCD = (UIP)W(U/P)1 (1)
where (U/P) and (U/P)1 refer to urine-to-midpoint plasma
concentration ratio of dextran and of inulin, respectively.
Afferent oncotic pressure (Ha) was calculated using the equa-
tion: H = aC + bC2 where C is the plasma protein concentration
and the coefficient a = 1.629 and b = 0.294 have been derived
by least analysis of the quadratic relationship between
plasma oncotic pressure and plasma protein concentration [171.
Efferent oncotic pressure (He) was derived from afferent pro-
tein concentration and filtration fraction.
Laboratory procedures
Plasma and urine sodium were determined by specific elec-
trodes using a multiparametric analyzer Hitachi 717 (Hitachi
Ltd., Tokyo, Japan), plasma and urine lithium by atomic
absorption spectrophotometry (PU 900U, PYE Unicam Ltd.,
Cambridge, UK); plasma and urine concentrations of inulin and
PAH by colorimetric methods [18, 19] performed on autoana-
lyzer I Technicon (Technicon Instrument Corp., Tarrytown,
New York, USA); hematocrit by routine Coulter counter
(Coulter Electronics, Hileah, Florida, USA). PRA was deter-
mined as the rate of formation of angiotensin I. Plasma aldo-
sterone was measured using a radioimmunoassay.
Dextran concentrations were analyzed after Zn(OH)2 depro-
teinization of each sample. Separation of dextran in protein-free
filtrates of plasma and urine into narrow fraction was achieved
by high-performance liquid chromatography on 2 Micropak
TSK columns in series (TSK 3000 and TSK 4000). The columns
were calibrated with four narrowly dispersed dextrans of
known molecular weight (81, 49, 24 and 12 kD, bought from
Pharmacosmos, Denmark). Blue dextran and alanin were used
to identify the void volume (Vo) and the total volume (Vt),
respectively. Dextran concentrations were measured using a
refractive index detector (R14, Varian Associates Inc., Palo
Alto, California, USA). An integrator (4400, Varian) was used
to divide the chromatogram into three slices per minute. The
integrated area of each slice was equated to the dextran
concentration at the corresponding retention time. Molecular
radius (re) was computed from the linear relationship between
retention time and molecular weight where r = 0.33 x (molec-
ular wt)°463. The fractional clearances of each discrete dextran
fraction at 2-A intervals over the molecular radius range (34 to
54 A) were computed using the equation (1).
Theoretical analysis of glomerular permselectivity
The glomerular filtration of macromolecules can be explained
using a theoretical model assimilating the glomerular capillary
wall to an ultrafiltration membrane with a negligible resistance
to the water, but discriminating molecules according to their
size and retaining all proteins of size equal to or larger than
albumin. A theoretical representation of this filtration process
with restriction according to size is given by the crossing
through a membrane perforated by restrictive filled water pores
[13, 20].
The permeability of the glomerular capillary wall to macro-
molecules can be studied by examining the sieving function of
macromolecules like dextrans (ramified dextrose polymers).
These components have a broad distribution of molecular radii,
ranging from those small enough to be freely filtered (20 A) to
those that are sufficiently large to be impermeant (70 A).
Dextran 40 is further uncharged, thereby permitting exclusive
evaluation of the size-selective properties of glomerular capil-
lary wall. Finally, dextran is neither reabsorbed nor secreted by
tubular cells and therefore the fractional clearance of dextran
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Table 1. Segmental tubular sodium handling before (control) and
after misoprostol (400 g orally) administration in 8 normal subjects
Control Misoprostol
CNa mi/mm 1.73 m2 2,54 0.2 2.49 0.34
UNaV mmol/min 364 29 357 49
FENa i0 21 2 22 2
CLI mi/mm 1.73 in2
FRL,
35.8 3.6
0.714 0.017
27.2 3C
0.760 0,018b
FDRNa 0.924 0.001 0.901 0.OOla
Abbreviations are: CNa, sodium clearance; UNOV, urinary sodium
excretion; FENa, fractional excretion of sodium; CLI, lithium clearance;
FRLI, fractional reabsorption of lithium; FDRNa, fractional distal reab-
sorption of sodium.
a p < b P < 0.01, C p < 0.001, misoprostol vs. control
over inulin represents the Bowman's space fluid to plasma
concentration ratio.
Among the several mathematical models that were developed
to describe the macromolecule filtration according to size
selectivity, Deen eta! have demonstrated that the "isopore with
shunt" model provides a more satisfactory representation of
dextran sieving curves in humans [13]. This model assumes the
existence of two populations of pores perforating the glomeru-
lar capillary wall: one population of restrictive, cylindrical
pores of identical radius r0 distributed on the major part of the
capillary wall and a second population of larger pores that do
not discriminate dextrans of high molecular weight. This "shunt
pathway" is characterized by a parameter w,, that governs a
small fraction of the filtrate volume passing through this non-
restrictive portion of the membrane. According to this model,
the membrane barrier to filtration of water and uncharged
macromolecules is characterized fully by the values of r0, o,,
and the ultrafiltration Kf.
In addition to these intrinsic membrane parameters that
govern the transmembrane flow of macromolecules, the filtra-
tion of dextran with a radius lower than 40 A is largely
influenced by the hemodynamic determinants of glomerular
ifitration, namely afferent oncotic pressure Ha, renal plasma
flow (RPF), and glomerular hydraulic pressure gradient P [20].
Applying a mathematical model to the dextrans sieving
curves and renal hemodynamics parameters (RPF, He, FF), a
set of the determinants AP, Kf, r0 and w, which fits best the
predicted and experimental values of dextran clearances, can
be calculated using the least square method (LOGINSERM,
Copyright 1991), which minimized the sum of between
calculated and observed sieving coefficients [13].
Statistical analysis
All the results were expressed as mean standard error.
After an analysis of variance (ANOVA) confirming the lack of
significant differences for each parameter among the three
control periods and among the three experimental periods, we
compared the average of the three control periods with the
average of the three experimental periods. Comparisons were
performed with an ANOVA for repeated measurements and
post-hoc tests when appropriate [21]. Differences were consid-
ered significant at the 0.05 level.
Table 2. Renal hemodynamics before (control) and after misoprostol
(400 g orally) administration in 8 normal subjects
Control Misoprostol
GFR ml/minI.73 m2 124 9 114 10
RPF mi/mm 1.73 in2 726 35 658 37
FF 0.172 0.001 0.172 0.007
MAP mm Hg 84.6 1.3 86.7 1.4
RVR mm Hg . mm/mi 78.5 4.6 89.6 42b
Abbreviations are: GFR, glomerular filtration rate; RPF, renal
plasma flow; FF, filtration fraction; MAP, mean arterial pressure; RVR,
renal vascular resistance.
ap < 0.05, bP < 0.01, C p < 0.001, misoprostol vs. control
Table 3. Determinants of glomerular filtration before (control) and
after misoprostol (400 sg orally) administration in 8 normal subjects
Control Misoprostol
HammHg 18±1 24±2C
llemmHg 29±2 32±1
zPmmHg 34±1 392b
Kf mi/mn/mm Hg
r0A
15.6 1.7
55±0.3
10.7 1.4k
55±0.2
% 0.27 0.03 0.30 0.06
Abbreviations are: Ha, afferent oncotic pressure; He, efferent oncotic
pressure; iSP, hydraulic transcapillary pressure gradient; K, ultraffitra-
tion coefficient; r0, mean effective radius of restrictive pores; w0,
fraction of filtrate passing through the shunt pathway.
a p < o,o5, b p < 0.01, P < 0.001, misoprostol vs. control
Results
Misoprostol study
When given orally, misoprostol is well and rapidly absorbed
with a maximal concentration reached at 30 minutes and an
elimination half life of 90 minutes, and has a number of
measurable systemic effects due to its excellent bioavailability
[22].
In our study, misoprostol did not change natriuresis, sodium
clearance or sodium fractional excretion (Table 1). However,
fractional lithium reabsorption (FRL) and presumably frac-
tional proximal reabsorption of sodium significantly increased
by 6.4%, whereas lithium clearance significantly decreased by
22%. In addition, fractional distal sodium reabsorption de-
creased significantly by 2%.
At the dose of 400 jg administered orally, misoprostol
significantly decreased GFR and renal plasma flow by 12 and
9%, respectively (Table 2). Filtration fraction was unchanged.
Mean arterial pressure tended to increase with marginal signif-
icance (0.05 <P < 0.06) and renal vascular resistance increased
significantly by 14%.
The effect of misoprostol on dextran sieving curve was
analyzed over the 34 to 54 A radii range. Misoprostol induced a
fall in the fractional clearance of small dextrans over the 36 to
42 A radius range (Fig. 1).
A mathematical analysis applying these sieving curves to a
model of isopore + shunt model of glomerular filtration enabled
to evaluate the variations of the determinants of glomerular
ultrafiltration (Table 3). Following misoprostol administration,
afferent oncotic pressure significantly increased by 33.3% while
efferent oncotic pressure was unchanged, the transcapillary
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Fig. 2. Dextran sieving curves (fractional dextran clearances) plotted
versus the effective molecular radius over the 34 to 54 A radius range,
before and after misoprostol (N = 8). Control is depicted as open
circles (mean SEM) and misoprostol as closed circles. Fractional
dextran clearances were significantly different over the 36 to 42 A radius
range. < 0.05; ** < 0.01
Control PGI2
CNa mI/mm . 1.73 m2 2.26 0.29 2.55 0.22
UNaV mmol/min
FENa•103
CLIm1/mnl.73m2
319 40
17±1
33±2
360 30
20±2a
32±2
FRLI
FDRNa
0.749 0.009
0.933 0.006
0.754 0.013
0.919 0.006"
pressure gradient (AP) significantly increased by 14.7% while
the ultrafiltration coefficient (Kf) significantly decreased by
31.4% (Fig. 2). The intrinsic membrane parameters r0 and o,,
were not modified.
At this specific dosage, misoprostol induced a significant and
consistent increase in plasma renin activity (5.6 1.8 vs. 1.1
0.5 nglmllhr; P < 0.01), whereas plasma aldosterone concen-
tration was unchanged (9.1 2.3 vs. 5.4 0.8 ng/dl; NS).
Prostacyclin study
Prostacyclin infusion exerted a slight natriuretic effect since
FENa significantly increased by 18% (Table 4). However, no
effect was demonstrated on lithium clearance and FRLI. Calcu-
lated FDRNa slightly, albeit significantly, decreased by 1.5%;
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Fig. 1. Changes in renal hemodynamics
before and during oral misosprostol
administration in 8 healthy subjects. Control
denotes the average value of three control
clearance periods obtained beforeControl S4 S5 S6 S7 misosprostol administration. S4 to S7 refers to
individual 30-minute experimental clearance
Periods periods following misoprostol administration.
Table 4. Segmental tubular sodium handling before (control) and
during prostacyclin (P012) infusion in 12 normal humans
**
**
**
*
Abbreviations are in Table 1.
p < 0.05, b p < 0.01, P012 vs. control
Effective molecular radius, A
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E
U-0
Periods
C Filtration fraction
Periods
100 D Renal vascular resistance
Fig. 3. Chart of changes in renal
hemodynamics before and during intravenous
prostacyclin administration in 12 healthy
subjects. Control denotes the average value of
the three control clearance periods obtained
before prostacyclin administration. S4 to S6
refers to individual 30-minute experimental
clearance periods following prostacyclin
administration.
Control P012
GRF mi/mm . 1.73 m2 133 8 132 7
RPF mI/mm' 1.73 m2 641 39 754 42"
FF 0.210 0.007 0.176 0.005
MAPmmHg 85.3±1.1 80.2±l.6a
RVRmm Hg . mm/mI 94 6 75 5b
this distal effect may account for the natriuretic effect of
prostacyclin.
Prostacyclin infusion did not change GFR but significantly
increased renal plasma flow by 18%, and hence, filtration
fraction significantly decreased by 19% (Table 5). Prostacyclin
significantly decreased mean aterial pressure and renal vascular
resistance by 6 and 20%, respectively (Fig. 3).
Dextran sieving curves before and after prostacyclin infusion
were evaluated over the 34 to 54A radii range (Fig. 4). A fall in
the fractional clearance of dextrans in the 34 to 48 A radius
range was found.
Prostacyclin effects on the determinants of glomerular filtra-
tion are presented in Table 6. Prostacyclin infusion induced
a9% increase in afferent oncotic pressure, while it decreased
efferent oncotic pressure by 8%.
The transcapillary hydraulic pressure gradient significantly
decreased by 13% whereas the ultrafiltration coefficient was
unchanged. The intrinsic membrane parameters r0 and w0 were
not modified.
30 40 50 60
Effective molecular radius, A
Fig. 4. Dextran sieving curves (fractional dextran clearances) plotted
versus the effective molecular radius over the 34 to 54 A radius range,
before and after prostacyclin (N = 12). Control is depicted as open
squares (mean SEM) and misoprostol as closed squares. Fractional
dextran clearances were significantly different over the 34 to 48 A radius
range. < 0.01; < 0.001.
Prostacyclin infusion did not influence significantly plasma
renin activity (0.9 0.2 vs. 1.2 0.7 ng/mllhr; NS) and plasma
aldosterone (8.2 1.7 vs. 6.2 0.7 ng/dl; NS).
A GFR B Renal plasma flow175
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Table 5. Renal hemodynamics before (control) and during
prostacycin (PGI2) infusion in 12 normal subjects
Abbreviations are in Table 2.
a P < 0.01, " P < 0.001, PGI2 vs. control
**
**
1
0.1
0.01
0.001
**
**
**
**
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Table 6. Determinants of glomerular filtration before (control) and
during prostacyclin (PGI2) infusion in 12 normal humans
Control PG!2
Ha mm Hg 19.8 0.5 27 0.9
HemmHg 35±1 31±la
APmmHg 35±1 32±la
Krnl mm/mm Hg
r0A
31.5 2.8
54±0.3
28.2 1.5
54±0.3
wo % 0.077 0.005 0.081 0.009
Abbreviations are in Table 3.
a P < 0.001, P012 vs. control
Discussion
In the present study we have studied in conscious supine and
sodium-repleted healthy subjects the renal effects of intrave-
nous PG!2 and oral misoprostol or 15-deoxy-16-hydroxy-!6-
methyl-PGE1, a synthetic analog of natural prostaglandin E
[221. We found that PGEI and PG!2 exerted opposite patterns of
changes in tubular reabsorption, renal hemodynamics and gb-
merular permselectivity. Some evidence further suggests that
these opposite changes could be related to different stimulatory
effect on renin secretion.
PGs are thought to play an important role in the renal
handling of sodium. Indeed, PGEs and PG!2 were found to
promote natriuresis in the dog and in humans [7, 12, 23—27]. In
our study PG!2 was found to be slightly natriuretic, presumably
in relation with a decrease in distal sodium reabsorption.
However, the latter result extrapolated from lithium clearance
should be interpreted with caution due to the elevation in
filtered load of sodium and the relatively constant fractional
reabsorption in the more proximal parts of the nephron. More-
over, the validity of lithium clearance as an index of distal
delivery has been questioned when manipulating prostaglan-
dins. Thus, inhibition of cyclooxygenase by indomethacin in
humans was found to increase FRLI presumably through an
effect within the loop of Henle [28].
It has been largely accepted in the literature that PGEs and
PGI2 induce natriuresis primarily through a decrease in filtra-
tion fraction and the resulting changes in peritubular capillary
Starling's forces, that is, increase in hydrostatic pressure and
decrease in oncotic pressure, or through "washout" of the
corticopapillary gradient by enhanced medullary blood flow
[29—32]. However, the decrease in filtration fraction has not
been consistently followed by a rise in natriuresis [26, 27], and
several studies demonstrated that prostaglandins could aug-
ment sodium excretion independently of changes in renal
hemodynamics, most likely by directly opposing tubular reab-
sorption beyond the proximal tubule, predominantly the med-
ullary TALH and collecting tubule [25, 33, 34]. Our results do
not contradict the preceding reports since, in our study, both
misoprostol and PG!2 could have decreased distal sodium
reabsorption through a direct inhibitory effect. However, mis-
oprostol also increased proximal reabsorption in relation with
several potential mechanisms including changes in proximal
peritubular capillary, Starling's forces, and stimulation of an-
giotensin II production within the renal interstitium [35].
The vascular effects of the prostaglandins of the E and I
series have been widely studied in the animal, but few studies
are available in humans. There is considerable evidence that
PGEs and prostacyclin are potent vasodilators in most species,
including humans, and in most vascular beds including the renal
vasculature. However, the renal vasodilative response to PGEs
and PGI2 was not uniform since PGEs and PG!2 induced renal
vasodilation in rabbit [36] and in dog [6—12] whereas they were
found to be renal vasoconstrictors in the rat [36—38]. Further-
more, within one species the vascular response may differ from
one vascular bed to another [39].
These conflicting results concerning the renovascular re-
sponse to PGEs and PG!2 could result from different basal renal
vascular tone. Indeed, according as the renal vasculature was
initially vasodilated or vasoconstricted the administration of
PGEs induced either weak constrictive or potent vasodilative
responses [40].
In our study, the renovascular response in normal humans to
a single oral dose of misoprostol and to a continuous infusion of
exogenous PGI2 was different. In our supine sodium repleted
healthy subjects, misoprostol induced significant renal vasocon-
striction and a trend toward higher mean arterial pressure.
Since GFR and renal plasma flow decreased in parallel, filtra-
tion fraction was unchanged. Our findings are in apparent
contradiction with the study of Conte et al [4!], who reported
that PGE1 induced renal vasodilation and increased GFR when
infused into healthy human subjects. This controversy could be
tentatively explained by the different route of administration
or the dosage of prostaglandin used. Of more concern, the
vasodilatory effect of PGEI reported by Conte et al was
observed in normal subjects submitted to maximal antidiuresis
by water deprivation and administration of l-deamino-8-D-
arginine-vasopres sin, all conditions favoring baseline renal vaso-
constriction. In another study, intravenous PGE2 was found to
increase renal plasma flow [42]. However, in the presence of
captopril, PGE2 significantly reduced blood pressure, GFR and
to a lesser extent renal plasma flow, suggesting that an intact
renin-angiotensin system is required to maintain GFR during
PGE2 infusion [42].
Furthermore, misoprostol stimulated renin secretion in our
study and hence the renal vasoconstriction could be have been
mediated by angiotensin II. The pattern of renal hemodynamic
changes induced by misoprostol was, however, not strictly
comparable to that usually reported with angiotensin II, since in
our study no change in filtration fraction was found [431.
In contrast to misoprostol, prostacyclin decreased systemic
blood pressure and exerted potent renal vasodilation while GFR
was not modified. Our results regarding PG!2 are consistent
with a number of studies reporting its renal vasodilatory effects
in humans. PG!2 administered at a dose of 6 ng kg .min
intravenously in humans significantly increased renal plasma
flow and slightly decreased diastolic blood pressure without
affecting systolic blood pressure and GFR [44]. Vasodilatory
effects were further reported when PGI2 was administered in
patients with renal ischemia [3]. In other studies, the stable
carbaprostacyclin analog, iloprost, increased significantly GFR
in patients with advanced obliterative arterial disease of the
extremities [45] and in patients with essential hypertension [46].
To characterize the determinants of the glomerular filtration
we studied fractional clearance of neutral dextran. Changes in
renal hemodynamics and in fractional clearances of dextran
were applied to a hydrodynamic model of filtration assimilating
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glomerular capillary barrier as a membrane perforated with
restrictive water-filled pores of identical mean radius r0 [13].
The filtration of neutral macromolecule of wide range of molec-
ular weight is further explicated by the presence of non-
restrictive pores quantified by the parameter cot,, which indi-
cates the fraction of the filtrate volume passing through this
shunt pathway according to the isopore plus shunt model
described previously by Deen et al [13].
Misoprostol decreased the fractional dextran clearances in
the 36 to 42 A radius interval. As GFR and renal plasma flow
were also slightly decreased we calculated that the decline in
the passage of small dextrans primarily resulted from a decrease
in Kf with a compensatory increase in hydraulic transcapillary
pressure gradient (P).
In contrast, PGI2 infusion induced a significant fall in the
fractional dextran clearances over the 34 to 48 A radius interval,
associated with an increase in renal plasma flow. These changes
were computed to result from a significant decrease in the
hydraulic transcapillary i.P and a nonsignificant reduction of
the glomerular capillary K. Both misoprostol and P012 did not
influence significantly the membrane parameters r,, and w,,,
indicating that variations in dextran clearances were primarily a
consequence of changes in convective fluxes regulated by the
determinants of glomerular hemodynamics [20, 47].
Micropuncture studies on the renal hemodynamic effects of
PGEs and PG!2 have been reported in the literature. Baylis et al
[48] have reported that mildly vasodepressor doses of POE1,
when infused into anesthetized Munich-Wistar rats, resulted in
a significant rise in glomerular plasma flow (QA) due to a fall
both in afferent (RA) and efferent (RE) arteriolar resistance, the
fall in RA being proportionately greater. The P remained
constant, but the glomerular capillary K decreased significantly
and single nephron glomerular filtration rate (SNGFR) did not
rise in spite of the marked increase in QA. In contrast, Schor
and Brenner [38] found that subvasodepressive doses of POE2
and PG!2 in the rats lowered SNGFR, QA and K, whereas P
and total renal vascular resistance increased. It should be
noticed that these changes, similar to those evoked by angio-
tensin II, were abolished when salarasin, a competitive angio-
tensin II receptor antagonist, was infused together with either
PGE2 or PGI2. Therefore, the effects of nonhypotensive doses
of POE2 and P012 on the renal microcirculation in anesthetized
rats could be mediated by angiotensin II, yet one cannot
preclude a potentiation by other endogenous vasoconstrictor
systems induced by anesthetic agents and/or surgical trauma.
We conclude that in normal humans PG!2 exerted potent
vasodilation and mild natriuresis whereas the PGEI analog,
misoprostol, evoked mild renal vasoconstriction but no natri-
uresis, effects that are likely related to stimulation of the
renin-angiotensin system. Results of studies with prostaglan-
dins differ notably according to dosage and routes of adminis-
tration that have different abilities to stimulate the renin-
angiotensin system. The renal effects of PGs depend primarily
on baseline renal vascular tone, initial status of the renin-
angiotensin system, and possibly according to species. Data
obtained from experiments with POEI and P012 in animals
undergoing anesthesia and/or surgical trauma should probably
not be extrapolated to conscious healthy humans.
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